Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer and infectious disease. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.
The company’s innovative products target post-translational modifications of proteins and lipids. For the vaccines this includes citrullination and homocitrullination of proteins, whereas the monoclonal antibodies target the glycans or sugars on proteins and/or lipids.